# US 9,060,974 B1 · Prostate cancer therapy using an engineered respiratory syncytial virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,060,974 B1
- Document ID: US9060974B1
- Status: Granted
- Kind: B1
- Application number: 13/134,326
- Filed: 2011-06-06
- Granted: 2015-06-23
- Earliest claimed: 2011-06-06
- Applicants: Weidong Zhang; Lixian Jiang; Calvin Cao
- Inventors: Weidong Zhang; Lixian Jiang; Calvin Cao
- Web page: https://patentgrep.com/patent/US9060974B1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2760/18032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18511: Pneumovirus, e.g. human respiratory syncytial virus
- C12N 2760/18532: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18543: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ΔNS1 RSV), kills prostate cancer cells, but does not affect normal human cells.

## Claims

### Claim 1

A method to treat prostate cancer in a patient in need thereof by delivering directly to the cancer an oncolytic engineered respiratory syncytial virus (RSV) with the NS1 gene deleted, wherein the RSV infects and causes oncolysis to thereby treat the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the engineered RSV is suspended in saline.

### Claim 3 (depends on 1)

The method of claim 1, wherein the engineered RSV is suspended in medium.